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Objective: The discovery of small molecular compounds that expand cartilage is needed. We searched for
small molecular compounds that expand cartilage or enhance the actions of bone morphogenetic
proteins (BMPs) on cartilage.
Design: Metatarsal primordial cartilage explants prepared from 14.5 days postcoitum (d.p.c.) mouse
embryos were organ-cultured in the presence or absence of BMPs and/or 4-(5-Benzol[1,3]dioxol-5-yl-4-
pyrldin-2-yl-1H-imidazol-2-yl)-benzamide hydrate (BPIB) and its related molecules. The perichondrium
was removed from some of the cartilage explants by partial digestion with collagenase. BPIB aqueous
solution was prepared by fragmenting BPIB crystals in water with laser irradiation and then added to
cartilage explants in organ culture.
Results: We found that small molecular compounds, BPIB, available as SB431542 from Sigma and its
related molecules, expand primordial cartilage explants in organ culture. These molecules are trans-
forming growth factor-b (TGF-b) inhibitors, and the addition of excess TGF-b reduced cartilage expansion
induced by these molecules. The co-administration of BPIB and BMPs synergistically expanded cartilage
explants. Removal of the perichondrium abolished BIPB-induced cartilage expansion but not BMP-
induced cartilage-expansion, suggesting that BPIB, but not BMPs, expands cartilage through the peri-
chondrium. Furthermore, we used the laser-ablation technique to generate BPIB aqueous solution in the
presence of 2-hydroxypropyl-b-cyclodextrin (HP-b-CD) without the use of hazardous dimethyl sulfoxide
(DMSO). The laser-ablation-generated BPIB aqueous solution was more stable, expanded cartilage
explants more effectively than BPIB colloidal solution prepared with DMSO, and synergistically enhanced
BMP-induced cartilage expansion.
Conclusions: A small molecular compound, BPIB, expands primordial cartilage explants. A BPIB aqueous
solution was created by laser-ablation without using DMSO and proved to be biologically active.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Limb skeletal components are initially formed by primordial
cartilage during embryogenesis. Chondrocytes in the central region
of each primordial cartilage segment undergo hypertrophy and are
gradually replaced by bone through the process called endochondral: Noriyuki Tsumaki, Depart-
Graduate School of Medicine,
81-6-6879-3398; Fax: 81-6-
(N. Tsumaki).
s Research Society International. Pbone formation1. This process is recapitulated in fracture healing. On
the other hand, cartilage at both ends of skeletal components
remains and serves as articular cartilage throughout life. Chon-
drocytes in articular cartilage seldom undergo hypertrophy. Loss of
articular cartilage due to arthritis, degeneration with age, or trauma
rarely heals and often results in osteoarthritis (OA) with pain on
motion2,3. No drugs are currently available to heal cartilage loss4.
Growth factors including transforming growth factor-b (TGF-b),
bone morphogenetic protein (BMP), insulin-like growth factor-1
(IGF-I), and ﬁbroblast growth factor (FGF) have positive effects on
cartilage regeneration. Proof of this concept has most often been
shown by studying the proliferation of chondrocytes or the differ-
entiation of mesenchymal stem cells to chondrocytes underublished by Elsevier Ltd. All rights reserved.
Fig. 1. BPIB and its related molecules enhanced the growth of cartilage in organ
culture. The metatarsal primordial cartilage from 14.5 d.p.c. mouse forelimbs was
dissected and cultured (day 0). On the following day, the medium was changed to
medium with or without compounds (day 1). (A) Searching for compounds that
enhance the growth of cartilage explants in organ culture. Cartilage explants were
cultured in the presence or absence of compounds for 6 days. Relative mean areas of
cartilage explants after culture (day 7). Mean areas of cartilage cultured in the absence
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reliably translated to in vivo models5. This discrepancy between
cultured chondrocytes and in vivo cartilagemay arise in part because
cartilage consists of extracellular matrix in addition to chondrocytes.
In the case of primordial cartilage, the cartilage is surrounded by
perichondrium. These additional components may respond to
growth factors in unexpected ways. In fact, TGF-b1 and FGF2 inhibit
the growth of metatarsal primordial cartilage in organ culture
systems6,7, although BMP7 promotes it8. Thus, BMPs are important
candidatemolecules for cartilage repair therapy9. Concomitantly, the
discovery of small molecular compounds that expand cartilage or
enhance the actions of BMPs on cartilage is needed.
In this report, we found that 4-(5-Benzol[1,3]dioxol-5-yl-4-pyrl-
din-2-yl-1H-imidazol-2-yl)-benzamide hydrate (BPIB, available as
SB431542 from Sigma), a small molecular compound, expands
cartilage explants in organ culture. The co-administration of BPIB and
BMPs synergistically expanded cartilage explants. Because BPIB and
its derivatives are insoluble in water, they are initially dissolved in
dimethyl sulfoxide (DMSO) and followed by addition to water or
medium to prepare colloidal solution in experimental settings.
However, it is necessary to dissolve or disperse them in water for
future clinical application without the use of hazardous DMSO. To
solve this problem, we utilized laser-ablation technique10e12 to
fragment the bulk crystal of BPIB, producing nanoparticles of BPIB.
We incorporated fragmented BPIB nanoparticles into the cavity of 2-
hydroxypropyl-b-cyclodextrin (HP-b-CD) to yield an isotropic
aqueous solution of BPIB. We proved that BPIB aqueous solution by
laser-ablation is stable and effectively expands cartilage explant. BPIB
aqueous solution by laser-ablation can be a candidate drug for
cartilage.
Materials and methods
Organ culture of metatarsal primordial cartilage
Second, third and fourth metatarsal primordial cartilage of
forelimb bud was cultured as described previously8. Metatarsal
cartilage was dissected from mouse embryos at 14.5 days post-
coitum (d.p.c.) and cultured in 500 ml a-modiﬁed essential medium
without nucleosides (Invitrogen) supplemented with 0.05 mg/ml
ascorbic acid (SigmaeAldrich), 0.3 mg/ml L-glutamine (Merck),
0.05 mg/ml gentamicin (Invitrogen), 0.25 mg/ml Fungizone
(Invitrogen), 1 mM b-glycerophosphate (Merck), and 0.2% FBS
(Gibco) in 24-well plates in a humidiﬁed atmosphere of 5% CO2 in
air at 37C (day 0). We collected six metatarsals from both forepaws
of each mouse embryo. One metatarsal was cultured in each well.
The number of metatarsals used in each experiment is indicated by
n in the Figures or Figure legends.
For experiments in which perichondrium was enzymatically
removed, the cartilage explants were incubated for 2 min at room
temperature in 1 mg/ml collagenase type 2 in phosphate buffered
saline (PBS), as previously reported13,14. Metatarsal cartilage from
one limb was stripped of the perichondrium, while the cartilage
from the contralateral limb was kept intact.of compounds were set as 1. P values were determined by the Student’s t-test. Error
bars show means 95% CIs. (B) Cartilage explants were cultured in the presence
(40 mM) or absence of compounds. Top, explants on day 1 and 7. Bottom, For quanti-
ﬁcation of cartilage growth, areas of cartilage explants were measured on images, and
the area on day 7 was divided by the area on day 1. Mean ratios of explant areas on day
7 to that on day 1 (n¼ 6, except for that SB505124 is n¼ 4). Error bars show
means 95% CIs. *P< 0.0001 (Welch’s t-test) as compared with the samples cultured
in the absence of compounds. (C) Inhibition of TGF-b signals by compounds. ATDC5
cells were transfected with p3TP-luc and cultured in medium supplemented with TGF-
b1 (2 ng/ml) and in the presence (10 mM) or absence of compounds. (n¼ 4, except for
that BPIB is n¼ 3). P value was determined by the Welch’s t-test.
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containing 10 or 40 mM of various compounds including BPIB, avail-
able as SB431542 from Sigma, 10 or 20 ng/ml of recombinant human
(rh) TGF-b1 (PeproTech EC), 400 ng/ml of rhGDF5 (RayBiotech;
Johnson and Johnson), 500 ng/ml of rhBMP2 (Yamanouchi), or 50 or
100 ng/ml FGF2 (PeproTech). Thereafter, the medium was changed
every other day. The cartilage explants were photographed on day 1
(before the addition of compounds or growth factors) and days 4, 5, 7,
and 11 with a Nikon Eclipse TE2000-U. Areas of total cartilage were
measured by using Scion Image software (Scion Corporation). For
each piece of cartilage, the areas at day 4, 5, 7, or 11 were divided by
the area on day 1 to determine the degree of growth.
For histological analysis, cartilage explants were ﬁxed overnight
at 4C in 4% paraformaldehyde, dehydrated through a series of
ethanol and xylene, embedded in parafﬁn, and sectioned. Histo-
logical sections were stained with safranin O/fast green/iron
hematoxylin. RNA in situ hybridization was performed by using
digoxigenin-11 UTP-labeled single-strand RNA probes. We gener-
ated antisense probes by using type II collagen gene (Col2a1) and
type X collagen gene (Col10a1) cDNAs.
Statistical analysis
Data are shown as averages and 95% conﬁdence intervals (CIs).
Chi-square goodness-of-ﬁt test showed that assumptions ofGaussian
distribution were fulﬁlled in all data. Assumption of homogeneous
variance was examined by F test. In Figs. 1A, 2, 3A, 4A, 5AeC, and
Supplementary Fig. 2, homogenous variances were assumed and the
Student’s t-test was used. In Figs. 1B, 1C, 4B, and 6B, homogenous
variances were not assumed and Welch’s t-test was used. P values
<0.05were considered to be statistically signiﬁcant. Excel (Microsoft)
and Statcel2 (OMS publishing Inc.) were used for data analysis.
Supplementary Materials and Methods are included in the
Supplementary Data.
Results
BPIB enhances the growth of cartilage in organ culture through
inhibition of TGF-b signaling
To identify candidate drugs for cartilage repair therapy, we used
a cartilage organ culture system to search for small molecular
compounds that enlarge cartilage. We dissected metatarsal
primordial cartilage from mouse embryos at 14.5 d.p.c and organ-
cultured the cartilage explants in the presence or absence of small
molecular compounds. We found that cartilage explants cultured
with BPIB, available as SB431542 from Sigma were signiﬁcantly
larger than explants cultured without BPIB [Fig. 1(A)]. SB203580, an
inhibitor of p38 mitogen-activated protein kinase (p38MAPK)Fig. 2. Impairment of BPIB-induced enhancement of cartilage growth by addition of TGF-b1
day 1 (n¼ 3). P values were determined by the Student’s t-test.pathways, did not affect cartilage size, and Ly294002, a phosphati-
dylinositol-30 kinase (PI3K) inhibitor, inhibited cartilage growth.
Because BPIB (SB431542) is an inhibitor of TGF-b signaling, we
examined whether other TGF-b inhibitor compounds enhance the
growth of cartilage explants. All of these inhibitor compounds are
insoluble inwater. Therefore, we dissolved them in DMSO to prepare
10 mM stock solutions. We added 4 ml of the stock solution to 1 ml of
medium to obtain a ﬁnal concentration of 40 mM of compounds and
0.4% v/v DMSO. In the absence of compounds, cartilage enlarged 1.6-
fold during 6 days of organ culture [Fig. 1(B)]. In the absence of
compounds, presence of 0.4% v/v DMSO in themediumdid not affect
cartilage growth compared with the medium without DMSO (data
not shown). Cartilage enlarged 3.2-fold in the presence of BPIB [Fig.1
(B)]. Other TGF-b signal inhibitor compounds including SB505124
(Sigma), TGF-b-RI kinase inhibitor II (Calbiochem), SB525334
(Sigma), A-83-01 (Sigma), D4476 (Sigma), and LY364974 (Sigma) also
signiﬁcantly enhanced the cartilage growth [Fig. 1(B)]. These
compounds suppressed the luciferase activities of p3TP-luc15
induced by TGF-b1 [Fig. 1(C)], indicating that they inhibited the
transcriptional activation of the Smad responsive promoter (TP) by
TGF-b. Interestingly, it has been reported that TGF-b inhibits the
growth of metatarsal primordial cartilage in organ culture7. We
examined whether an excess amount of TGF-b cancels the effects of
BPIB on cartilage growth and found that the enhanced growth of
primordial cartilage caused by BPIBwas decreased by TGF-b1 [Fig. 2].
These results suggest that the inhibition of TGF-b signals in cartilage
enhances cartilage growth in organ culture.
BPIB and BMPs synergistically enhance growth of primordial
cartilage
Growth and differentiation factors (GDFs) belong to the BMP
family. The addition of GDF5 (400 ng/ml) to organ cultures of meta-
tarsal primordial cartilage resulted in enhanced cartilage growth
[Fig. 3(A)], which is consistent with a previous report that BMP7
enhances cartilage growth8. The addition of both BPIB and GDF5 to
the medium synergistically enhanced cartilage growth [Fig. 3(A)].
The synergistic effects were also recognized between other TGF-b
inhibitors (D4476 and TGF-b-RI KI II) and GDF5 [Fig. 3(A)]. Cartilage
explants treatedwith BPIB and/or GDF5 were positively stainedwith
Safranin O. The treated explants had an increased population of cells
expressing type II collagen, as determined by in situ hybridization
analysis [Fig. 3(B)], and had increased glycosaminoglycan content
[Fig. 4(A)], as compared to the untreated controls. These results
suggest that the volumeof hyaline cartilage increased after treatment
with BPIB and GDF5. On the other hand, cartilage explants treated
with BPIB and/or GDF5 showed an increased population of cells
expressing type X collagen [Fig. 3(B)], suggesting that BPIB and GDF5
accelerate the hypertrophy of chondrocytes as well as the expansion. Left, cartilage explant on day 7. Right, mean ratios of explant areas on day 7 to that on
Fig. 3. BPIB and BMPs synergistically enhance cartilage growth. Cartilage explants were cultured in the presence or absence of BPIB and GDF5 for 6 days (day 1eday 7). (A) BPIB and
its related molecules synergistically enhanced cartilage growth induced by GDF5. Left, cartilage explant on day 7. Right, mean ratios of explant areas on day 7 to that on day 1 (n¼ 3).
Error bars show means 95% CIs. *P< 0.0001 (Student’s t-test). Scale bars, 1 mm. (B) In situmRNA expression analysis of cartilage explants. Semiserial sections of cartilage explants
on day 7 were stained with Safranin O-fast green-iron hematoxylin and hybridized with type II collagen gene (Col2a1) and type X collagen gene (Col10a1) cRNA probes. Red color
staining with safranin O suggests the presence of glycosaminoglycans, a component of cartilage matrix. Type II collagen is a major cartilage-speciﬁc matrix component. Type X
collagen is a maker for hypertrophic cartilage. Scale bar, 300 mm.
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enhancement of cartilage growthwere also recognized betweenBPIB
and BMP2 [Fig. 4(B)].
To examine whether BPIB and GDF5 also affect articular carti-
lage in this culture system, we dissected the epiphyses of proximal
humeri collected from 8-week-old mice and cultured themwith or
without BPIB and GDF5 [Supplementary Table 1]. Articular cartilagewas signiﬁcantly thickened by addition of GDF5, but not by addition
of BPIB, as compared to the control.
BPIB and BMP expand cartilage through different mechanisms
We then analyzed how BPIB enhances cartilage growth. BrdU
labeling revealed that the addition of BMP2 or BPIB increased the
Fig. 4. BPIB increased glycosaminoglycan content and synergistically enhanced cartilage growth with BMP2. (A) Sulfated glycosaminoglycan content in organ-cultured primordial
cartilage in the presence or absence of BPIB and GDF5. P values were determined by the Student’s t-test. (B) BPIB synergistically enhanced the expansion of primordial cartilage
induced by BMP2. Left, cartilage explant on day 7. Scale bar, 1 mm. Right, mean ratios of explant areas on day 7 to that on day 1 (BMP2 (e), n¼ 3; BMP2 (þ), n¼ 4). P values were
determined by the Welch’s t-test. Error bars show means 95% CIs.
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[Fig. 4(A)]. On the other hand, the addition of BPIB reduced the
number of dispersed primary chondrocytes in monolayer cell
culture. Themean cell numbers of primary chondrocytes cultured in
the presence or absence of BPIB for 4 days (n¼ 3) were: BPIB (e),
3.701.14 (105); and BPIB (10 mM), 2.10 0.74 (105) (P¼ 0.0071,
as determined by the Student’s t-test). These results suggest that the
direct action of BPIB on chondrocytes is inhibition of proliferation.
This result is consistent with the previous ﬁndings that the in vitro
effects of TGF-b on chondrocyte proliferation are stimulatory16.
Cartilage consists of chondrocytes embedded in an extracellular
matrix and is surrounded by perichondrium, a membranous
connective tissue composed of several cell layers. Therefore, we
examined whether the perichondrium plays a role in the
enhancement of cartilage growth by BPIB. We stripped off the
perichondrium by digesting metatarsal cartilage with collagenase
for 2 min, according to the previously described methods13,14.
Primordial cartilage treated with collagenase collapsed on day 5,
probably because of the disruption of the perichondriumwhichmay
contribute to lining cartilage tissue. Therefore, we compared carti-
lage on day 4 with cartilage on day 1. The application of BPIB to
stripped cartilage did not signiﬁcantly enhance cartilage growth,
whereas BMP2 signiﬁcantly enhanced the growth [Fig. 4(C)]. These
results are consistent with the previous reports that TGF-b inhibits
the growth of metatarsal cartilage explants by affecting cells in the
perichondrium6. These results suggest that BPIB primarily acts on
perichondrial cells, which in turn stimulate the proliferation of
chondrocytes in cartilage. On the other hand, BMPsmay directly act
on chondrocytes and stimulate their proliferation in cartilage. A
previous report suggests that FGFs secreted from perichondrium
mediate TGF-b-induced inhibition of cartilage expansion7. TGF-
b stimulates the expression of FGF, which acts directly on chon-
drocytes and inhibits their proliferation. Thus, we examinedwhether exogenous FGFs can inhibit cartilage growth caused by
BPIB. The addition of FGF2 (100 ng/ml) signiﬁcantly decreased the
growth of cartilage cultured in the presence of BPIB [Fig. 5(C)]. Based
on these results, we speculate that BPIB induces the expansion of
primordial cartilage at least partially through the downregulation of
FGF function.
BPIB aqueous solution by laser-ablation expands cartilage explants
effectively
Next, we dispersed BPIB in water by using laser-ablation
technique10e12 without using hazardous DMSO [Supplementary
Fig. 1]. We investigated the stability of BPIB solutions at various
concentrations.WedilutedastockBPIBaqueoussolutiongeneratedby
laser irradiation with water (BPIB/laser aqueous solution). We also
diluted a stock BPIB solution dissolved in DMSO with water (BPIB/
DMSO colloidal solution). After BPIB/laser aqueous solutions (10 and
43 mM)were allowed to stand for 11 days, their absorbance decreased
by less than 3% as compared to freshly prepared BPIB/laser aqueous
solutions (day 0) [Fig. 6(A)]. On the other hand, the absorbance of
a BPIB/DMSO colloidal solution (43 mM) decreased gradually with
timeascompared totheabsorbanceofa freshlypreparedsolution (day
0), such that the absorbancedecreased by 46%after 11 days [Fig. 6(A)].
We then compared the biological effects of BPIB/laser aqueous
solution and BPIB/DMSO colloidal solution on cartilage explant
cultures. A stock BPIB aqueous solution generated by laser irradiation
or a stock BPIB solution dissolved in DMSO was added to medium to
a ﬁnal concentration of 1, 10, or 43 mM. We cultured metatarsal
cartilage explants in the BPIB-containing medium for 7 or 11 days.
The cartilage growth in the BPIB/laser aqueous medium was
enhanced in a dose-dependentmanner [Fig. 6(B)]. On the other hand,
the BPIB/DMSO colloidal medium did not increase the cartilage
growth in a dose-dependent manner [Fig. 6(B)]. Cartilage growth in
Fig. 5. Effects of BPIB on cartilage were abolished without perichondrium. (A) Proliferation rates of chondrocytes in cartilage explant cultured in the presence of BMP2 or BPIB for 3 days
(days 1e4) increased as comparedwith those in the absence of BMP2 and BPIB, as indicated by the increased numbers of BrdU-positive cells. Immunohistochemistry of cartilage explants
on day 4with anti-BrdU antibodies. Scale bar, 50 mm.Mean ratios (95% CIs) of BrdU-positive nuclei (n¼ 3)were: control (e), 3.221.08%; BMP2 (500 ng/ml) 13.56 6.15% (P¼ 0.0021);
and BPIB (10 mM) 9.28 2.80% (P< 0.0001). P value (Student’s t-test) as compared with the control (e). (B) After perichondrium was stripped from cartilage by partial digestion with
collagenase,metatarsal explantswere cultured in thepresence orabsenceofBMP2orBPIB for 3 days (days1e4). Growthof stripped cartilagewas enhancedbyaddition ofBMP2, but not by
addition of BPIB. Shown are cartilage explants on day 1 and 4. Scale bar,1 mm.Mean ratios (95%CIs) of explant areas on day 4 (mm2) to that on day 1 (mm2) (n¼ 3, except for that BPIB is
n¼ 4) were: control (e), 1.36 0.45; BMP2 (500 ng/ml) 3.30 1.05 (P¼ 0.0019); and BPIB (10 mM) 1.53 0.40 (P¼ 0.3592). P value (Student’s t-test) as compared with the control (e).
(C) Metatarsal explants were cultured in the presence or absence of BPIB or FGF2 for 6 days (days 1e7). BPIB-induced cartilage expansionwas reduced by addition of FGF2. Left, cartilage
explants on day 7. Scale bar, 1 mm. Right, mean ratios of explant areas on day 7 to that on day 1 (n¼ 3). P values were determined by the Student’s t-test.
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BPIB/laser aqueous medium at concentrations of 43 mM for 7-day
cultures and 10 and 43 mM for 11-day cultures. Differences in the
cartilage growth between BPIB/laser aqueous medium and BPIB/
DMSO colloidal medium at higher concentrations and longer culture
periods may be associated with differences in the stabilities of BPIB/
laser aqueous solution and BPIB/DMSO colloidal solution [Fig. 6(A)].
We ﬁnally conﬁrmed that BPIB dispersed in water by laser
irradiation and GDF5 synergistically enhanced the growth of
cartilage explants [Supplementary Fig. 2]. These results suggest
that BPIB aqueous solution generated through laser irradiation
without the use of DMSO is biologically functional.
Discussion
There is a signiﬁcant need for the discovery of small molecular
compounds that expand cartilage. In the present study,we found that
small molecular compounds, BPIB and its related molecules, expandcartilage explants in organ culture. In addition, these compounds
synergistically enhanced BMP-induced expansion of cartilage. These
molecules are TGF-b signal inhibitors. However, TGF-b has been
considered to be a growth factor that facilitates cartilage produc-
tion16. Previously reported ﬁndings and the present study suggest
that BPIB primarily acts on perichondrial cells, which in turn stimu-
late the proliferation of chondrocytes in cartilage. These indirect
effects of molecules on chondrocytes cannot be found in screening
systems that use primary chondrocytes. Thus, organ culture systems
that use cartilage tissue are useful for screening drugs for cartilage
expansion that have beenmissed in experiments that usemonolayer
cultures of chondrocytes.
BMPs and their subfamily, GDFs, are candidate molecules for the
regeneration of cartilage17,18. Although both BMPs and TGF-bs belong
to the TGF-b superfamily, their effects on primordial cartilage are
different. BMPs stimulate chondrogenic differentiation of mesen-
chymal cells and expand cartilage19,20. The overall effects of TGF-bs
on chondrocyte proliferation are stimulatory, but the response to
Fig. 6. BPIB dispersed by laser irradiation was more stable and enhanced growth of cartilage in organ culture more effectively than BPIB colloidal solution prepared by using DMSO.
(A) Stabilities of BPIB/laser aqueous and BPIB/DMSO colloidal solution at various concentrations. After preparation of solutions (day 0), solutions were left to stand for 7 or 11 days,
and the absorption spectra were measured. Absorptions of 43 mM BPIB/laser aqueous and BPIB/DMSO colloidal solution just after preparation by dilution (day 0) are set as 1. (B) Top,
Cartilage explants cultured in BPIB/laser aqueous medium and BPIB/DMSO colloidal medium on day 1, day 7 and day 11. Bottom, Growth of cartilage explants for 6 days (left graph)
and 10 days (right graph) (n¼ 6). P values were determined by the Welch’s t-test. Error bars show means 95% CIs.
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chondrocyte hypertrophy19,20, whereas TGF-bs inhibit chondrocyte
hypertrophy16. BMPs are clinically used to enhance fracture heal-
ing21,22. BMPs may contribute to expanding cartilaginous callus and
accelerate bone healing in the fracture repair process in which
endochondral ossiﬁcation is recapitulated. On the other hand, the
acceleration of hypertrophy caused by BMPs could be a disadvantage
during the repair of articular cartilage. In the present study, BPIBincreased both the glycosaminoglycan content and the population of
hypertrophic chondrocytes in a similar manner as GDF5. The
increased level of glycosaminoglycan caused by BPIB is favorable, but
the increase in hypertrophy is a disadvantage when considering the
application of BPIB to the repair of articular cartilage. In addition,
embryonic cartilage and mature articular cartilage are different
tissues and may respond to biological stimulations differently. BPIB
appeared to expand cartilage through the perichondrium. However,
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ably limited. In fact, we did not ﬁnd signiﬁcant effects of BPIB on
articular cartilage in organ culture. The precise effects of BPIB on
articular cartilage remain to be examined. On the other hand, the
synergistic effects of BPIB and BMPs on cartilage expansion and
hypertrophy suggest that BPIB can modulate the process of endo-
chondral bone formation, which is recapitulated in fracture healing.
Our results suggest that BPIB primarily acts on perichondrial
cells which in turn stimulate the proliferation of chondrocytes in
cartilage, whereas BMPs may directly act on chondrocytes and
stimulate their proliferation in cartilage. The difference in imme-
diate target cells between BPIB and BMPs may account for the
synergistic effect of thesemolecules on cartilage expansion. Clinical
applications of BMPs, such as for fracture treatment21,22 and spinal
fusion23, require a large dose. The combined application of BMPs
with BPIB and related molecules will decrease the amount of BMPs
needed for an advantageous clinical outcome. In addition, we
succeeded in preparing BPIB aqueous solution by laser-ablation-
induced fragmentation of BPIB bulk crystals into nanoparticles,
possibly followed by subsequent stabilization in the cavity of b-CD
in water. The BPIB aqueous solution by laser irradiation was more
stable and expanded cartilage explants more effectively than BPIB
colloidal solution prepared with DMSO. To the best of our knowl-
edge, this is the ﬁrst generation of biologically active aqueous
solution prepared by laser-ablation technique. This could be a new
method of preparing biologically active aqueous solutions of small
molecular compounds that are insoluble in water. Collectively,
these results may contribute to understanding the effects of TGF-
b signals on cartilage and developing safe and effective therapeutic
methods for diseases in which cartilage is involved.
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